Mucosta tablets 100 mg for ulcer and gastritis (rebamipide, Rebagen, Rebagit)

General information on Japanese Mucosta tablets 100 mg for ulcer and gastritis (rebamipide, Rebagen, Rebagit)

Package details: 100 tablets

Manufacturer: Otsuka Pharmaceutical Co., Ltd., Japan

Active ingredient: rebamipide (chemical formula C19H15ClN2O4)

Medical effect: Mucosta tablets are effective for the treatment of the following diseases and conditions:

• gastric ulcer,
• acute exacerbation of chronic gastritis,
• gastric mucosal lesions (erosion, bleeding, redness and edema) in acute gastritis,
• aphthous ulcer.

Contraindications and precautions: do not use for pregnant or breastfeeding women.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Mucosta tablets 100 mg from Japan for ulcer and gastritis (rebamipide, Rebagen, Rebagit)

For gastric ulcer: for adults, take 1 tablet (100 mg of active ingredient) 3 times a day in the morning, evening, and before going to bed.

For gastric mucosal lesions (erosion, bleeding, redness, and edema) in acute gastritis and acute exacerbation of chronic gastritis: for adults, take 1 tablet (100 mg of active ingredient) 3 times a day.

How effective are Mucosta tablets 100 mg from Japan for ulcer and gastritis (rebamipide, Rebagen, Rebagit)?

Mucosta tablets contain rebamipide, an amino acid derivative of 2-(1H)-quinolinone. It protects against gastric mucosal injury by increasing the prostaglandin E2 content and exerting a cytoprotective effect on the gastric mucosa. Also, Mucosta tablets increase the amount of gastric mucus and stimulate gastric mucosal blood flow to improve impaired hemodynamics, thus helping to suppress inflammation and repair the gastric mucosa.

Who should take Mucosta tablets 100 mg from Japan?

Mucosta tablets are effective for the treatment of gastric ulcer and for improvement of gastric mucosal lesions (erosion, bleeding, redness and edema) in acute gastritis and acute exacerbation of chronic gastritis. Also, studies showed that rebamipide in its usual dosage (3 tablets * 100 mg daily) is effective for the treatment of recurrent aphthous ulcers or stomatitis or mucositis, Behcet's syndrome and related diseases (Mohan H. Kudur, Manjunath Hulmani. “Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome”. Indian Journal of Dermatology. 2013, September-October, 58(5): 352–354).